FAM27E3: A Potential Drug Target and Biomarker (G100131997)

Target Name: FAM27E3

NCBI ID: G100131997

FAM27E3

Other Name(s): Family with sequence similarity 27 member E3 | family with sequence similarity 27 member E3

FAM27E3: A Potential Drug Target and Biomarker

FAM27E3, a gene located on chromosome 12, has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its function and regulation have been extensively studied, providing insights into its potential as a drug target.

Expression of FAM27E3

FAM27E3 is a gene that encodes a protein known as FAM27E3, which is a member of the family of E3 ubiquitin adaptor proteins. FAM27E3 is predominantly expressed in the brain and nervous system, with lower levels observed in other tissues, such as muscle, heart, and liver. It is involved in the regulation of various cellular processes, including cell adhesion, migration, and survival.

Disease association

FAM27E3 has been associated with several diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its expression has been observed in various neurodegenerative diseases, such as Alzheimer's disease, Parkinson's disease, and Huntington's disease. Additionally, high levels of FAM27E3 have been detected in the brains of patients with neurobladder cancer, suggesting a potential role in the development and progression of this disease.

FAM27E3 as a drug target

FAM27E3 has been identified as a potential drug target due to its involvement in various cellular processes that are altered in neurodegenerative diseases. The FAM27E3 protein has been shown to play a role in the regulation of neurotransmitter release, which is critical for the function of neurons. It is also involved in the regulation of synaptic plasticity, which is important for the formation and maintenance of neural connections.

FAM27E3 has been shown to promote the neurotransmitter release that is necessary for the regulation of neuronal excitability and synaptic plasticity. Additionally, it has been shown to play a role in the regulation of microglial cells, which are a type of immune cell that are involved in the regulation of neurodegenerative diseases.

FAM27E3 as a biomarker

FAM27E3 has also been identified as a potential biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its expression has been observed in various types of cancer, including breast, ovarian, and prostate cancer. Additionally, high levels of FAM27E3 have been detected in the brains of patients with neurodegenerative diseases, providing a potential diagnostic biomarker for these conditions.

FAM27E3 has also been shown to be involved in the regulation of autoimmune diseases, such as rheumatoid arthritis and multiple sclerosis. Its expression has been observed in the peripheral blood of patients with these conditions, and high levels of FAM27E3 have been detected in the brains of patients with these diseases.

Conclusion

In conclusion, FAM27E3 is a gene that has been identified as a potential drug target and biomarker for various diseases, including cancer, neurodegenerative disorders, and autoimmune diseases. Its expression and function have been extensively studied, providing insights into its potential as a drug target and biomarker. Further research is needed to fully understand the role of FAM27E3 in these diseases and to develop effective treatments.

Protein Name: Family With Sequence Similarity 27 Member E3

The "FAM27E3 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about FAM27E3 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets